00:47 , Mar 2, 2019 |  BC Extra  |  Company News

Emerging company roundup: Anthos, Maze, Oyster Point

In a week that had at least four companies post venture raises north of $80 million, Maze Therapeutics and Anthos Therapeutics Inc. had the biggest hauls, with financings near or above $200 million. Blackstone partnered...
01:31 , Mar 1, 2019 |  BC Week In Review  |  Financial News

Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

Oyster Point Pharma Inc. (Princeton, N.J.) raised $93 million on Feb. 26 in a series B round, which the company believes will provide enough runway to take one of its dry eye disease candidates through...
14:01 , Feb 26, 2019 |  BC Extra  |  Financial News

Oyster Point raises $93M series B to bring dry eye nasal spray to FDA

Oyster Point Pharma Inc. (Princeton, N.J.) raised $93 million Tuesday in a series B round, which the company believes will provide enough runway to take one of its dry eye disease candidates through an NDA...
00:50 , Jan 5, 2019 |  BC Extra  |  Company News

Flurry of management moves on eve of JPM

More than 30 biopharma companies announced executive changes to kick off the New Year, including Ironwood Pharmaceuticals Inc. (NASDAQ:IRWD) and Immunocore Ltd. (Abingdon, U.K.), both of which brought on former AstraZeneca plc (LSE:AZN; NYSE:AZN) executives...
01:44 , Jan 4, 2019 |  BC Week In Review  |  Clinical News

‘Tentative’ FDA approval for Braeburn's opioid addiction product

Braeburn Pharmaceuticals Inc. (Plymouth Meeting, Pa.) said FDA granted “tentative” approval to Brixadi buprenorphine (CAM2038) extended-release weekly and monthly injections to treat moderate-to-severe opioid use disorder. The drug is for use in patients who have...
19:29 , Dec 21, 2018 |  BC Week In Review  |  Company News

Amgen pulls out of Advaxis immunotherapy deal

Advaxis Inc. (NASDAQ:ADXS) will continue to enroll patients in a Phase I trial of its ADXS-NEO program despite Amgen Inc. (NASDAQ:AMGN) pulling out of a 2016 deal to develop the immunotherapy. Advaxis shares slid 37%...
19:46 , Nov 1, 2018 |  BC Innovations  |  Emerging Company Profile

Secarna’s next-gen oligos

Secarna Pharmaceuticals GmbH’s antisense oligonucleotides for immuno-oncology could have better tissue penetration than small molecules and antibodies against the same targets. The company was established in 2015 by the founders and investors who launched antisense...
22:52 , Oct 26, 2018 |  BC Extra  |  Company News

Management tracks: Principia, Orexo, Polyphor, MeiraGTx

Immunology and oncology company Principia Biopharma Inc. (NASDAQ:PRNB) hired Dolca Thomas as CMO. She succeeds Steve Gourlay, who will remain as a senior medical adviser through mid-2019. Thomas was VP and global head of translational...
16:36 , Oct 26, 2018 |  BC Week In Review  |  Clinical News

Oyster Point's OC-01 dry eye nasal spray meets in Phase IIb

Oyster Point Pharma Inc. (Princeton, N.J.) said all three doses of OC-01 met the primary endpoint of improving tear production in the Phase IIb ONSET trial to treat dry eye disease. The company also reported...
18:02 , Oct 25, 2018 |  BC Innovations  |  Distillery Therapeutics

Neurology

INDICATION: Cognitive dysfunction Mouse studies suggest inhibiting microglial activation could help treat obesity-associated cognitive dysfunction. In hippocampal tissue from a mouse model of obesity-associated cognitive dysfunction, microglia activation scores were higher than in normal mice....